Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLC · NSCLC (Non-small Cell Lung Carcinoma) · NSCLC (Advanced Non-small Cell Lung Cancer)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 590 (planned)
- Started
- May 6, 2025
- Main results expected
- Dec 1, 2027
- Fully finished
- Dec 1, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
Measured over: Up to approximately 4 years
Overall survival (OS) in the RAS G12X-C population
Measured over: Up to approximately 4 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT06881784 · record last updated 2026-11-06 · checked 2026-11-09 15:47 UTC